Public health officials are concerned over new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerging in various parts of the world.
The B.1.1.7 variant was first found in the United Kingdom and found to have the N501Y mutation that allows it to have a faster transmission rate than previous strains.
The B.1.351 variant was detected in South Africa and also has the N501Y genetic mutation observed in B.1.1.7. However, scientists are also concerned over two other genetic mutations — K417N and E484K — that have shown an ability to evade the immune system. Prior evidence has found the B.1.351 variant resistant to neutralizing antibodies produced from either prior infection or vaccination.
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Ongoing research is looking at how to slow the spread of these variants. Currently, the total number of global COVID-19 cases has reached over 112 million. There are also more than 2.4 million global deaths.
Understanding how these variants become more deadly is necessary for finding the appropriate target to neutralize them.
New research by a team of scientists at Stanford University School of Medicine in the U.S. found that both variants display tighter binding to the human angiotensin-converting enzyme 2 (ACE2) receptor. This receptor allows SARS-CoV-2 to enter and infect host cells.
The study results “SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity” are available as a preprint on the bioRxiv* server, while the article undergoes peer review.
How they did it
The team used an experimental tool called Microscale Thermophoresis to investigate how the B.1.1.7 and B.1351 variants become more infectious and how their spike proteins’ receptor binding domain interacts with the human ACE2 protein.
Specifically, the receptor-binding domain of B.1.1.7 and B.1351 was compared with the receptor-binding domain of Hu-1— the SARS-CoV-2 strain that was initially detected in Wuhan, China.
Spike proteins of both variants bound tighter to ACE2
Results showed a greater binding affinity between B.1.1.7’s receptor-binding domain and ACE2 compared to Hu-1’s binding affinity. B.1.1.7 showed a 1.98-fold higher affinity.
Binding affinity with ACE2 was highest with the B.1.351 variant. There was a 4.62-fold greater affinity compared to Hu-1.
These findings suggest that acquisition of enhanced affinity of Spike proteins for the human ACE2 receptor may be a convergent feature of more transmissible SARS-CoV-2 variants arising in multiple geographic regions and indicate that MST provides a rapid way to biochemically assess such changes.”
Based on the findings, the researchers suggest the results are consistent with previous models that also attributed both variants’ increased transmissibility with greater binding affinity with human ACE2.
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Article Revisions
- Apr 5 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses